Literature DB >> 19898501

Pre-transplant risk factors affecting outcome in Hurler syndrome.

P J Orchard1, C Milla, E Braunlin, T DeFor, K Bjoraker, B R Blazar, C Peters, J Wagner, J Tolar.   

Abstract

Allogeneic transplantation remains the standard of care for patients with Hurler syndrome. As enzyme replacement therapy (ERT) has become available, controversy has emerged in regards to whether the use of enzyme in the peri-transplant period is appropriate. An analysis was performed on 74 patients with Hurler syndrome transplanted at the University of Minnesota between 1990 and 2003, before our use of ERT associated with transplant, with the intention of determining if patients at higher risk during the transplant can be identified based on evaluations and events before transplantation. Age, the presence of hydrocephalus, a history of cardiovascular issues or upper airway obstruction before transplant was not associated with significant differences in survival. In contrast, patients who had a history of lower airway disease, including reactive airway disease or bronchiolitis, or a history of pneumonia, had a significantly inferior outcome based on OS. The risk for serious respiratory complications was also assessed by evaluating the incidence of intubation. Overall, 31% of these patients were intubated. The risk of intubation was higher in older patients and in those with a history of lower airway disease. These findings have implications for the care of patients with high-risk features.

Entities:  

Mesh:

Year:  2009        PMID: 19898501     DOI: 10.1038/bmt.2009.319

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

Review 1.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

2.  Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome.

Authors:  Julie B Eisengart; Kyle D Rudser; Jakub Tolar; Paul J Orchard; Teresa Kivisto; Richard S Ziegler; Chester B Whitley; Elsa G Shapiro
Journal:  J Pediatr       Date:  2012-09-10       Impact factor: 4.406

3.  Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience.

Authors:  Nathan J Rodgers; Alexander M Kaizer; Weston P Miller; Kyle D Rudser; Paul J Orchard; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2017-01-04       Impact factor: 4.982

4.  Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation.

Authors:  Hannah Y Coletti; Mieke Aldenhoven; Karina Yelin; Michele D Poe; Joanne Kurtzberg; Maria L Escolar
Journal:  JIMD Rep       Date:  2015-01-23

5.  Fatal and unanticipated cardiorespiratory disease in a two-year-old child with hurler syndrome following successful stem cell transplant.

Authors:  Sampada Gupta; Anne O'Meara; Robert Wynn; Michael McDermott
Journal:  JIMD Rep       Date:  2013-03-09

6.  Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres.

Authors:  Arunabha Ghosh; Weston Miller; Paul J Orchard; Simon A Jones; Jean Mercer; Heather J Church; Karen Tylee; Troy Lund; Brian W Bigger; Jakub Tolar; Robert F Wynn
Journal:  Mol Genet Metab       Date:  2016-01-27       Impact factor: 4.797

7.  The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.

Authors:  Matt S Zinter; Caroline A Lindemans; Birgitta A Versluys; Madeline Y Mayday; Sara Sunshine; Gustavo Reyes; Marina Sirota; Anil Sapru; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

8.  Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.

Authors:  Kristin D'Aco; Lisa Underhill; Lakshmi Rangachari; Pamela Arn; Gerald F Cox; Roberto Giugliani; Torayuki Okuyama; Frits Wijburg; Paige Kaplan
Journal:  Eur J Pediatr       Date:  2012-01-11       Impact factor: 3.183

Review 9.  Anaesthesia and airway management in mucopolysaccharidosis.

Authors:  Robert Walker; Kumar G Belani; Elizabeth A Braunlin; Iain A Bruce; Henrik Hack; Paul R Harmatz; Simon Jones; Richard Rowe; Guirish A Solanki; Barbara Valdemarsson
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

10.  Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison.

Authors:  Julie B Eisengart; Kyle D Rudser; Yong Xue; Paul Orchard; Weston Miller; Troy Lund; Ans Van der Ploeg; Jean Mercer; Simon Jones; Karl Eugen Mengel; Seyfullah Gökce; Nathalie Guffon; Roberto Giugliani; Carolina F M de Souza; Elsa G Shapiro; Chester B Whitley
Journal:  Genet Med       Date:  2018-03-08       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.